Top Dividend Stocks to Buy: J&J and AbbVie
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 15 hours ago
0mins
Should l Buy JNJ?
Source: Fool
- Strong Dividend Growth: Johnson & Johnson, a Dividend King, has raised its dividends for 50 consecutive years, reflecting its stable financial health and long-term investment appeal, with future sales expected to grow despite challenges from patent expirations and government price negotiations.
- Diversified Product Portfolio: Johnson & Johnson boasts a wide range of products across pharmaceuticals and medical devices, with ongoing innovations helping it maintain a competitive edge, and the recently launched Ottava robotic-assisted surgery device is anticipated to further drive revenue growth.
- Consistent Dividend Returns: AbbVie has increased its dividends for 54 straight years since going public in 2013, showcasing its strong profitability and stable cash flow, particularly with impressive performance in its immunology and oncology product lines, making it an ideal choice for long-term investors.
- Innovative Capability and Market Adaptability: AbbVie quickly returned to revenue growth after losing Humira's patent, demonstrating its robust innovation capabilities, and is expected to be well-prepared to address patent expirations in the 2030s, ensuring its long-term dividend payment capacity.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 242.990
Low
190.00
Averages
218.50
High
240.00
Current: 242.990
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson Receives FDA Approval for New Intraocular Lens
- FDA Approval: Johnson & Johnson's Tecnis PureSee intraocular lens has received FDA approval, marking it as the first extended depth of focus IOL, providing a new option for cataract surgery that is expected to enhance surgical outcomes and patient satisfaction.
- Visual Quality Improvement: The lens maintains contrast sensitivity, ensuring that patients can better differentiate objects from backgrounds post-surgery, thereby reducing dependence on glasses and improving overall quality of life for users.
- Positive User Feedback: JNJ reports that 97% of users have not experienced halos, glare, or other visual disturbances after implantation, indicating strong clinical performance that may drive increased market demand for the product.
- Product Line Expansion: Tecnis PureSee will be the latest addition to J&J's Tecnis lens portfolio, further enriching its product offerings and strengthening the company's competitive position in the ophthalmic market, which is expected to positively impact future sales.
See More
Top Dividend Stocks to Buy: J&J and AbbVie
- Strong Dividend Growth: Johnson & Johnson, a Dividend King, has raised its dividends for 50 consecutive years, reflecting its stable financial health and long-term investment appeal, with future sales expected to grow despite challenges from patent expirations and government price negotiations.
- Diversified Product Portfolio: Johnson & Johnson boasts a wide range of products across pharmaceuticals and medical devices, with ongoing innovations helping it maintain a competitive edge, and the recently launched Ottava robotic-assisted surgery device is anticipated to further drive revenue growth.
- Consistent Dividend Returns: AbbVie has increased its dividends for 54 straight years since going public in 2013, showcasing its strong profitability and stable cash flow, particularly with impressive performance in its immunology and oncology product lines, making it an ideal choice for long-term investors.
- Innovative Capability and Market Adaptability: AbbVie quickly returned to revenue growth after losing Humira's patent, demonstrating its robust innovation capabilities, and is expected to be well-prepared to address patent expirations in the 2030s, ensuring its long-term dividend payment capacity.
See More
Pfizer Stock Shows Signs of Reversal Potential
- Technical Reversal Signals: Pfizer's stock has formed a series of higher lows over the past year, breaking above its downtrend since the 2024 peak, indicating potential for a reversal that may provide investors with a timely re-entry opportunity.
- Defined Support Levels: The stock's downside support is clearly defined around the rising 50-day moving average, forming an ascending triangle with a breakout target of $30.50, suggesting a favorable risk/reward scenario in the current market environment.
- Improving Momentum Indicators: The Relative Strength Index (RSI) is trending higher and not overbought, indicating enhanced buying momentum, allowing investors to consider buying on recent weakness to capitalize on a potential rally above $27.50 towards $30.
- Safe Dividend Yield: With a current dividend yield of 6.4%, Pfizer, as part of the large pharma sector, may serve as a safe haven for investors amid increasing market volatility, providing stable returns with relatively low risk.
See More
Investment Opportunity Analysis for S&P 500 Index
- Market Volatility Analysis: The S&P 500 index has recently experienced multiple fluctuations, with investors facing concerns over AI spending and economic growth, particularly due to escalating conflict in Iran, leading to a bearish market sentiment and unpredictable short-term outlook.
- Historical Performance Review: Despite current market instability, the S&P 500 has historically recovered from every dip, with an average annual return of 10%, demonstrating its reliability as a long-term investment, especially crucial during uncertain times.
- Vanguard ETF Investment Advantage: Investing in the Vanguard S&P 500 ETF (VOO) is a smart choice as it mimics the S&P 500 composition, ensuring investors achieve the same performance as the benchmark, with quarterly adjustments reflecting market changes, providing stable exposure to economically driven companies.
- Diversification Investment Strategy: This ETF includes 11 industries, such as technology, healthcare, and financials, effectively diversifying risk and mitigating the impact of sharp movements in any single stock or industry, with long-term holding expected to yield positive returns.
See More
Global Investors Reassess US Stocks Amid Iran War
- Market Performance Reversal: Following the outbreak of the Iran war, the U.S. stock market has shifted from being the worst performer to the best, indicating a resurgence of investor confidence in U.S. equities amidst rising global uncertainties.
- Portfolio Restructuring: As investors reassess risks, many are scaling back their 'Sell America' bets and seeking refuge in the U.S., the world's most liquid market, which has contributed to a recent boost in the dollar's value.
- Energy Market Advantage: The U.S., as a net energy exporter, benefits from oil prices rising above $100 per barrel, contrasting with Europe and Asia, which are net importers and have smaller energy sectors, exacerbating regional market performance disparities.
- Defensive Sector Performance: Although defensive sectors like consumer staples, healthcare, and telecoms have underperformed during recent market fluctuations, this suggests a rotation rather than a straightforward risk-off approach, indicating a strategic shift towards more promising markets.
See More
Johnson & Johnson Receives FDA Approval for New Intraocular Lens
- FDA Approval: Johnson & Johnson announced that its TECNIS PureSee IOL has received FDA approval as a new extended depth of focus intraocular lens for cataract surgery, marking an important new option for surgeons.
- Enhanced Visual Clarity: The TECNIS PureSee IOL allows 97% of patients to report no very bothersome visual disturbances, significantly improving visual quality and enhancing daily activities such as reading, driving, and recognizing faces.
- Dual Functionality: This lens addresses both cataract-related vision loss and presbyopia in a single procedure, showcasing its multifunctionality in ophthalmic surgery and further solidifying Johnson & Johnson's market position in the eye care sector.
- Global Recognition: The TECNIS PureSee IOL is approved worldwide, with nearly half a million eyes experiencing clearer vision after cataract surgery, demonstrating the product's broad acceptance and successful application in the global market.
See More
Johnson & Johnson Receives FDA Approval for New Intraocular Lens
- FDA Approval: Johnson & Johnson's Tecnis PureSee intraocular lens has received FDA approval, marking it as the first extended depth of focus IOL, providing a new option for cataract surgery that is expected to enhance surgical outcomes and patient satisfaction.
- Visual Quality Improvement: The lens maintains contrast sensitivity, ensuring that patients can better differentiate objects from backgrounds post-surgery, thereby reducing dependence on glasses and improving overall quality of life for users.
- Positive User Feedback: JNJ reports that 97% of users have not experienced halos, glare, or other visual disturbances after implantation, indicating strong clinical performance that may drive increased market demand for the product.
- Product Line Expansion: Tecnis PureSee will be the latest addition to J&J's Tecnis lens portfolio, further enriching its product offerings and strengthening the company's competitive position in the ophthalmic market, which is expected to positively impact future sales.
See More
Top Dividend Stocks to Buy: J&J and AbbVie
- Strong Dividend Growth: Johnson & Johnson, a Dividend King, has raised its dividends for 50 consecutive years, reflecting its stable financial health and long-term investment appeal, with future sales expected to grow despite challenges from patent expirations and government price negotiations.
- Diversified Product Portfolio: Johnson & Johnson boasts a wide range of products across pharmaceuticals and medical devices, with ongoing innovations helping it maintain a competitive edge, and the recently launched Ottava robotic-assisted surgery device is anticipated to further drive revenue growth.
- Consistent Dividend Returns: AbbVie has increased its dividends for 54 straight years since going public in 2013, showcasing its strong profitability and stable cash flow, particularly with impressive performance in its immunology and oncology product lines, making it an ideal choice for long-term investors.
- Innovative Capability and Market Adaptability: AbbVie quickly returned to revenue growth after losing Humira's patent, demonstrating its robust innovation capabilities, and is expected to be well-prepared to address patent expirations in the 2030s, ensuring its long-term dividend payment capacity.
See More
Pfizer Stock Shows Signs of Reversal Potential
- Technical Reversal Signals: Pfizer's stock has formed a series of higher lows over the past year, breaking above its downtrend since the 2024 peak, indicating potential for a reversal that may provide investors with a timely re-entry opportunity.
- Defined Support Levels: The stock's downside support is clearly defined around the rising 50-day moving average, forming an ascending triangle with a breakout target of $30.50, suggesting a favorable risk/reward scenario in the current market environment.
- Improving Momentum Indicators: The Relative Strength Index (RSI) is trending higher and not overbought, indicating enhanced buying momentum, allowing investors to consider buying on recent weakness to capitalize on a potential rally above $27.50 towards $30.
- Safe Dividend Yield: With a current dividend yield of 6.4%, Pfizer, as part of the large pharma sector, may serve as a safe haven for investors amid increasing market volatility, providing stable returns with relatively low risk.
See More
Investment Opportunity Analysis for S&P 500 Index
- Market Volatility Analysis: The S&P 500 index has recently experienced multiple fluctuations, with investors facing concerns over AI spending and economic growth, particularly due to escalating conflict in Iran, leading to a bearish market sentiment and unpredictable short-term outlook.
- Historical Performance Review: Despite current market instability, the S&P 500 has historically recovered from every dip, with an average annual return of 10%, demonstrating its reliability as a long-term investment, especially crucial during uncertain times.
- Vanguard ETF Investment Advantage: Investing in the Vanguard S&P 500 ETF (VOO) is a smart choice as it mimics the S&P 500 composition, ensuring investors achieve the same performance as the benchmark, with quarterly adjustments reflecting market changes, providing stable exposure to economically driven companies.
- Diversification Investment Strategy: This ETF includes 11 industries, such as technology, healthcare, and financials, effectively diversifying risk and mitigating the impact of sharp movements in any single stock or industry, with long-term holding expected to yield positive returns.
See More
Global Investors Reassess US Stocks Amid Iran War
- Market Performance Reversal: Following the outbreak of the Iran war, the U.S. stock market has shifted from being the worst performer to the best, indicating a resurgence of investor confidence in U.S. equities amidst rising global uncertainties.
- Portfolio Restructuring: As investors reassess risks, many are scaling back their 'Sell America' bets and seeking refuge in the U.S., the world's most liquid market, which has contributed to a recent boost in the dollar's value.
- Energy Market Advantage: The U.S., as a net energy exporter, benefits from oil prices rising above $100 per barrel, contrasting with Europe and Asia, which are net importers and have smaller energy sectors, exacerbating regional market performance disparities.
- Defensive Sector Performance: Although defensive sectors like consumer staples, healthcare, and telecoms have underperformed during recent market fluctuations, this suggests a rotation rather than a straightforward risk-off approach, indicating a strategic shift towards more promising markets.
See More
Johnson & Johnson Receives FDA Approval for New Intraocular Lens
- FDA Approval: Johnson & Johnson announced that its TECNIS PureSee IOL has received FDA approval as a new extended depth of focus intraocular lens for cataract surgery, marking an important new option for surgeons.
- Enhanced Visual Clarity: The TECNIS PureSee IOL allows 97% of patients to report no very bothersome visual disturbances, significantly improving visual quality and enhancing daily activities such as reading, driving, and recognizing faces.
- Dual Functionality: This lens addresses both cataract-related vision loss and presbyopia in a single procedure, showcasing its multifunctionality in ophthalmic surgery and further solidifying Johnson & Johnson's market position in the eye care sector.
- Global Recognition: The TECNIS PureSee IOL is approved worldwide, with nearly half a million eyes experiencing clearer vision after cataract surgery, demonstrating the product's broad acceptance and successful application in the global market.
See More
